
---
title: 'Nirma大学_ 用于肺癌管理的纳米生物载体'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/60.png'
author: 科学网
comments: false
date: Thu, 02 Sep 2021 20:39:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/60.png'
---

<div>   
<section><strong style="box-sizing: border-box;">Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers</strong></section><p></p><section><section><section><section><section>Shruti Rawal, Mayur Patel*<p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><strong style="box-sizing: border-box;"><em style="box-sizing: border-box;">Nano-Micro Letters </em><em style="box-sizing: border-box;">(2021)</em><em style="box-sizing: border-box;">13: 142 </em></strong></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><em style="box-sizing: border-box;">https://doi.org/10.1007/s40820-021-00630-6</em></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6424" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/60.png" alt width="440" height="302" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p></section></section></section></section></section><section></section><section><section><strong style="box-sizing: border-box;">本文亮点</strong></section></section><section><section><section><section><section><section><section></section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><em style="box-sizing: border-box;"><strong style="box-sizing: border-box;">1</strong></em><em style="box-sizing: border-box;"><strong style="box-sizing: border-box;">. </strong></em>综述介绍了影响<strong style="box-sizing: border-box;">肺癌预后的因素</strong>、各种<strong style="box-sizing: border-box;">纳米生物工具</strong>，以及它们相对于传统纳米载体在肺癌治疗方面的优势。</section><section><em style="box-sizing: border-box;"><strong style="box-sizing: border-box;">2.</strong></em> 由于<strong style="box-sizing: border-box;">纳米生物载体和纳米生物设备</strong>在肿瘤学多方面的应用，因此被认为是未来治疗癌症的重要工具。</section><section><em style="box-sizing: border-box;"><strong style="box-sizing: border-box;">3. </strong></em>本文对整体肺癌管理的相关调查、观点和规定的研究进行了深入的思考和探索。</section></section><section></section><section><section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section></section><section><section><section><strong style="box-sizing: border-box;">内容简介</strong></section></section></section><section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section></section></section><section>全球癌症发病率不断上升，肺癌被认为是最致命的癌症形式之一，具有复杂的临床影响和不良的预后。纳米生物工程是一门应用科学，通过设计新的纳米生物工具和策略，可以在临床方面辅助治疗和革新肺癌诊断方式。纳米生物工程目前研究了许多新型的生物纳米装置，并将其应用扩展到放射治疗、免疫治疗、光疗、基因治疗、和联合疗法以及促进肺癌多模式肿瘤靶向的新疗法。寻找合适的靶向治疗策略也引发了称为“纳米生物载体”的新型纳米载体的开发。其中，纳米生物载体多是生物工程、仿生、生物源和生物混合纳米载体、细胞或囊泡。与其他纳米载体不同，纳米生物载体具有多靶点、高生物交互性、生物相容性强、内在伪装和可扩展性等明显优势。Nirma大学Mayur Patel课题组探讨了近年来纳米生物工程以及纳米技术的发展在肺癌临床管理方面的研究进展。深入讨论了生物纳米工具，如纳米生物载体和纳米生物设备在肺癌的二级预防、诊断、治疗和治疗学的应用，分析了具有应用前景的生物工程、生物仿生和仿生纳米生物工具。</section><section></section><section><section><strong style="box-sizing: border-box;">图文导读</strong></section></section><section><section><section><section><section><section><section></section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><strong style="box-sizing: border-box;">I</strong><strong style="box-sizing: border-box;"> </strong><strong style="box-sizing: border-box;">当前肺癌管理方法面临的挑战</strong><section>尽管肺癌的诊断和治疗取得了进步，但肺癌仍然是一种不治之症。几十年来，化学预防和癌症疫苗开发一直是肿瘤学研究的对象，但尚未通过临床评估得到证实。此外，成像和筛查技术取得了相当大的进步，但目前的检测技术无法诊断疾病的早期阶段。由于患者的高度多样性，常规诊断方法缺乏对肿瘤亚型的分子/遗传变异的识别。</section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">基于纳米载体的治疗、生物治疗和免疫治疗已在临床上成为手术和放疗的辅助和新辅助治疗。随着用于治疗非小细胞肺癌 (NSCLC) 的新型靶向生物制剂和免疫治疗剂的出现，治疗结果和患者存活率有了相当大的改善。然而，其他亚型肺癌如小细胞肺癌(SCLC)和恶性胸膜间皮瘤的治疗方案仍需改善。因此，更深入地了解肺癌发生、进展和转移中的细胞、遗传和分子改变对于促进新靶点的识别至关重要。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">治疗药物监测和治疗诊断学的概念仍处于其发展的初级阶段，需要进行广泛的研究。在这种情况下，寻求生物纳米技术来预防、诊断和治疗肺癌是至关重要的。</p><section><strong style="box-sizing: border-box;">II</strong><strong style="box-sizing: border-box;"> </strong><strong style="box-sizing: border-box;">纳米生物工程和不同类型的生物纳米工具</strong></section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">不同的生物纳米技术衍生工具，如纳米生物载体和纳米生物设备，在应对肺癌治疗的问题上引起了巨大的科学兴趣。其中用于肿瘤学应用的生物纳米载体可以概括为：(1)微生物纳米系统和生物纳米载体(2)细胞和细胞膜衍生的纳米系统(3)配体偶联的纳米系统(4)纳米生物设备，如图1。</p><section><img class="alignnone  wp-image-6425" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/61.png" alt width="427" height="390" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图1. 用于肿瘤学应用的生物纳米载体和纳米生物设备。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">基于微生物的纳米系统正逐渐应用于临床中，其中，已用于治疗恶性肿瘤的不同微生物纳米生物载体包括：细菌、生物工程细菌、细菌微细胞、S-膜衍生的纳米囊泡、磁小体、细菌幽灵、细菌衍生的外膜囊泡(蛋白脂质体)(OMV)、细菌聚合物、生物工程病毒、噬菌体和病毒以及真菌和酵母。因为微生物对特定细胞/器官的先天性，以及生物组学和生物工程技术的进步，增强了微生物的纳米系统的载体化潜力。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">目前，基于细胞和细胞膜衍生的靶向肿瘤载体包括基于红细胞(如图2所示)、白细胞 (WBC)、单核细胞/巨噬细胞、树突状细胞、中性粒细胞、淋巴细胞、血小板、间充质细胞 (MSC)、癌细胞、细胞外囊泡和外泌体衍生的纳米生物载体。除了仿生伪装外，基于细胞的纳米生物载体还表现出优异的生物相容性、多分子和内在靶向能力、自我隐身能力以及对多种肿瘤应用有利的宿主生物整合的能力。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6426" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/62.png" alt width="443" height="332" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图2. 使用红细胞(RBC)搭便车治疗肺部 B16-F1的转移模型。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">常规纳米系统/纳米颗粒经过修饰后，通过天然、生物工程、生物启发或生物衍生的生物分子促进肿瘤靶向。为了有效地靶向肿瘤，纳米这种生物载体可以是以下亚型之一：缀合物(药物-生物聚合物)、纳米储库(用作电晕/表面涂层的生物分子)或纳米基质(纳米系统是完全由生物分子制造)。其中，生物分子包括抗体，脂蛋白, 蛋白质和肽类,肺表面活性剂和维生素等，可被生物分子修饰的常规纳米载体包括基于脂质的纳米颗粒，聚合物纳米颗粒等。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">纳米生物设备是通过生物纳米技术，为各种临床和生物医学应用制造的小工具、设备、设计或其组件。根据构造材料，纳米生物设备包括基于微生物、免疫传感器、DNA和组织四种类型。</p><section><strong style="box-sizing: border-box;">III</strong><strong style="box-sizing: border-box;"> </strong><strong style="box-sizing: border-box;">用于肺癌临床管理的纳米生物载体</strong></section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">生物纳米技术协助癌症药物发现和开发。在发展靶向疗法，发现和鉴定新的细胞、生物分子和分子靶标等方面，纳米生物工程的工具推进了药物发现和药物开发的过程。此外，纳米生物载体在肺癌的二级预防、诊断、治疗和治疗学方面起着重要的作用。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">通过纳米生物载体，开发癌症疫苗和免疫疗法，这些疫苗和免疫疗法对高危患者(恶性肿瘤)具有治疗和预防作用。因此，纳米生物载体可用于肺癌的二级预防。基于甘露糖化纳米颗粒的疫苗(如图3)可以促进树突状细胞的递送，并可以刺激针对癌细胞的免疫反应。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6427" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/63.png" alt width="441" height="333" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图3. 基于甘露糖基LCP纳米颗粒(MN-LCP-NP)用于树突细胞(DCC)激活的疫苗。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">通过纳米生物技术，提高生物成像和鉴定肿瘤相关分子标志物的能力，最终实现肺癌纳米生物诊断以及个性化治疗。图4开发了一种新型纳米生物杂化物，促进肺癌的多模态(MRI成像和显微PET)成像。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6428" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/64.png" alt width="515" height="239" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图4. (i) Mn2⁺-OCT-PEG-MNPs的体外和体内MRI分析；(ii) PET分析12⁴I标记的Mn2⁺-OCT-PEG-MNPs。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">纳米生物工程不仅帮助药物开发，还可以促进药物递送。迄今为止，发展了四代纳米载体，促使肿瘤治疗从“被动靶向”向“主动靶向”转变。纳米生物工程和生物纳米技术在多种类型治疗(如化疗、光疗(如图5所示)、免疫治疗、基因/表观遗传疗法(如图6所示)、放射治疗(如图7所示)、联合治疗和新型抗癌疗法(如图8所示))的药物递送中，具有多功能性和多模式适用性。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6429" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/65.png" alt width="486" height="617" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图5. 开发了PAAO-UCNPs-GOx用于增强肺癌的光疗。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6430" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/66.png" alt width="367" height="438" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图6.  开发了具有由pH敏感脂质组成的纳米生物载体，用于递送防止肺癌转移扩散的siRNA。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6431" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/67.png" alt width="388" height="409" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图7. 开发了一种纳米生物载体(C@siPLK1-NH)，用于非小细胞肺癌细胞(NSCLC)的放射增敏。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><img class="alignnone  wp-image-6432" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/68.png" alt width="355" height="376" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">图8. 开发了一种靶向 EGFR 的纳米生物载体，通过诱导细胞凋亡和自噬发挥协同抗癌活性。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">纳米生物治疗学是指单一药剂的统一诊断和治疗应用。目前使用的纳米生物治疗学包括无机纳米粒子、纳米笼、纳米壳、二氧化硅、脂质体、树枝状聚合物、胶束和其他生物组成的金属有机框架。随着生物纳米技术的进步，基于病毒、基于蛋白质的纳米生物载体已被用于肺癌治疗诊断中。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;"><strong style="box-sizing: border-box;">IV</strong><strong style="box-sizing: border-box;"> </strong><strong style="box-sizing: border-box;">总结与展望</strong></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">随着纳米生物科学和生物纳米技术的发展，可以大大克服肿瘤靶向方式中的障碍，具有改变当前肿瘤治疗状态的巨大潜力。目前，大量不同的纳米工具和新型纳米系统被广泛探索，解决传统疗法面临的各种问题，应用于肿瘤(包括肺癌)的预防、诊断、治疗和各方面。生物纳米技术工具可以通过分子诊断和先进的生物成像技术，设计新的治疗策略来加强肿瘤治疗。纳米生物载体是通过个性化和定制药物递送解决肿瘤异质性的有用手段。同时，纳米医学的转化应用也面临着巨大挑战，与跨学科研究人员之间的知识融合还有待加强。</p></section><section><section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section></section><section><section><section><strong style="box-sizing: border-box;">作者简介</strong></section></section></section><section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section><section><section><section><section></section></section></section></section></section></section></section></section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px; text-align: center;"><img class="alignnone  wp-image-6433" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/69.png" alt width="103" height="131" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"><strong style="box-sizing: border-box;">Mayur Patel</strong></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px; text-align: center;">本文通讯作者</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px; text-align: center;"><strong style="box-sizing: border-box;">Nirma University 副教授</strong></p></section></section></section><section><section>▍<strong style="box-sizing: border-box;">主要研究领域</strong></section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">药剂学，新型给药系统，结肠靶向。</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">▍<strong style="box-sizing: border-box;">主要研究成果</strong></p><section>发表21篇国际和国家出版物，总影响因子超过60，总引用次数超过700，h指数为12。</section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">▍<strong style="box-sizing: border-box;">Email: </strong><strong style="box-sizing: border-box;">drmayurmpatel@gmail.com</strong></p><section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px; text-align: center;"><img class="alignnone  wp-image-6434" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/09/70.png" alt width="106" height="134" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"><strong style="box-sizing: border-box;">Shruti Rawal</strong></p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px; text-align: center;">本文第一作者</p><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px; text-align: center;"><strong style="box-sizing: border-box;">Nirma University 博士研究生</strong></p></section></section></section><section><section>▍<strong style="box-sizing: border-box;">主要研究领域</strong></section><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">肿瘤学，配方开发，生物技术治疗诊断学，营养品。</p><section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section>撰稿：《纳微快报(英文)》编辑部</section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section><section>编辑：《纳微快报(英文)》编辑部</section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section></section><section><section><section><section><section><section></section></section></section></section><section><section><strong style="box-sizing: border-box;">关于我们</strong></section></section><section><section><section><section></section></section></section></section><section><section><strong style="box-sizing: border-box;">纳微快报</strong></section></section><section><section><section><section></section></section></section></section></section></section><section><img class="alignnone  wp-image-6330" src="https://cors.zfour.workers.dev/?http://www.nmsci.cn/wp-content/uploads/2021/08/310.png" alt width="203" height="278" style="box-sizing: border-box; border: 0px; vertical-align: middle; margin: 0px auto; display: block; height: auto;" referrerpolicy="no-referrer"><p style="box-sizing: border-box; margin-top: 0px; margin-bottom: 16px;">Nano-Micro Letters《纳微快报(英文)》是上海交通大学主办、Springer Nature合作开放获取(open-access)出版的英文学术期刊，主要报道纳米/微米尺度相关的高水平文章(research article, review, communication, commentary, perspective, letter, highlight, news, etc)，包括微纳米材料的合成表征与性能及其在能源、催化、环境、传感、吸波、生物医学等领域的应用研究。已被SCI、EI、SCOPUS、PubMed Central、DOAJ、CSCD、知网、万方、维普、超星等数据库收录。2020 JCR影响因子IF=16.419，在物理、材料、纳米三个领域均居Q1区(前10%)。2020 CiteScore=15.9，材料学科领域排名第4 (4/123)。中科院期刊分区：材料科学1区TOP期刊。全文免费下载阅读(http://springer.com/40820)，欢迎关注和投稿。<br></p><section><strong style="box-sizing: border-box;">E-mail：</strong>editor@nmletters.org</section><section><strong style="box-sizing: border-box;">Tel：</strong>021-34207624</section></section><p></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自纳微快报科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-3411509-1302588.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-3411509-1302588.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-3411509-1301720.html" target="_black">NML综述 | 范壮军教授：用于高能量/高功率密度超级电容器的过渡金属化合物-碳杂化电极研究进展</a><br>                    <!--大赛结束-->
                                        
  
</div>
            